In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 5, 2008, Pages 466-475

  Hellum, Bent H ^a,b   Nilsen, Odd Georg ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Medical Technical Research Center Trondheim   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYTESTOSTERONE; AESCULUS HIPPOCASTANUM EXTRACT; COMMON SAGE EXTRACT; COMPLEMENTARY DNA; CYTOCHROME P450 3A4; DIGOXIN; ECHINACEA PURPUREA EXTRACT; ECHINAGARD; GINKGO BILOBA EXTRACT; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; HYPERICUM STADA; KETOCONAZOLE; NOSWEAT; PLANT EXTRACT; SEREDRIN; TESTOSTERONE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG; VALERIAN; VALERINA; VENASTAT; VERAPAMIL;

ARTICLE; BACULOVIRUS; CELL STRAIN CACO 2; COMMON SAGE; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MEDICINAL PLANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCINTILLATION; TRANSPORT KINETICS; VALIDITY;

CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DIGOXIN; HERB-DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; P-GLYCOPROTEIN; PLANT EXTRACTS; PLANT PREPARATIONS; TESTOSTERONE; VERAPAMIL;

AESCULUS; ECHINACEA PURPUREA; GINKGO BILOBA; VALERIANA OFFICINALIS;

EID: 42149119034     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00227.x     Document Type: Article

References (69)

1. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E et al. Herb-drug interactions: a literature review. Drugs 2005 65 : 1239 82.
2. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003 35 : 35 98.
3. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004 36 : 57 104.
4. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003 43 : 149 73.
5. Guengerich FP. In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 1996 24 : 521 33.
6. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997 29 : 413 580.
7. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003 42 : 59 98.
8. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003 55 : 3 29.
9. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987 84 : 7735 8.
10. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995 13 : 129 34.
11. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ et al. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000 68 : 598 604.
12. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003 73 : 41 50.
13. Veronese ML, Gillen LP, Burke JP, Dorval EP, Hauck WW, Pequignot E et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003 43 : 831 9.
14. Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007 100 : 23 30.
15. Dresser GK, McDonald W, Kim RB, Bailey DG. Evaluation of herbal products as potential inhibitors of MDR1. Clin Pharmacol Ther 2004 75 : 79.
16. Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 2006 27 : 543 54.
17. Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003 20 : 1184 91.
18. Eagling VA, Wiltshire H, Whitcombe IW, Back DJ. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 2002 32 : 1 17.
19. Tuvesson H, Hallin I, Persson R, Sparre B, Gunnarsson PO, Seidegard J. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos 2005 33 : 866 72.
20. Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. J Agric Food Chem 2007 55 : 7620 5.
21. Busby WF Jr., Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos 1999 27 : 246 9.
22. Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998 26 : 207 15.
23. Chauret N, Gauthier A, Nicoll-Griffith DA. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998 26 : 1 4.
24. Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol 2007 101 : 350 8.
25. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003 290 : 1500 4.
26. Donovan JL, DeVane CL, Chavin KD, Wang JS, Gibson BB, Gefroh HA et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004 32 : 1333 6.
27. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005 11 : 433 9.
28. Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 2004 318 : 1072 8.
29. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005 77 : 415 26.
30. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004 11 : 98 104.
31. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000 7 : 273 82.
32. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004 32 : 512 8.
33. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001 70 : 317 26.
34. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T et al. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005 78 : 25 33.
35. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y et al. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005 22 : 525 39.
36. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006 46 : 1290 8.
37. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004 76 : 428 40.
38. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004 75 : 89 100.
39. Modarai M, Gertsch J, Suter A, Heinrich M, Kortenkamp A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 2007 59 : 567 73.
40. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006 34 : 786 92.
41. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999 99 : 552 7.
42. Lowes S, Cavet ME, Simmons NL. Evidence for a non-MDR1 component in digoxin secretion by human intestinal Caco-2 epithelial layers. Eur J Pharmacol 2003 458 : 49 56.
43. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 2006 78 : 2131 45.
44. Yang CY, Chao PD, Hou YC, Tsai SY, Wen KC, Hsiu SL. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol 2006 44 : 1572 8.
45. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004 11 : 262 77.
46. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002 71 : 414 20.
47. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997 53 : 587 96.
48. Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 2006 78 : 2116 30.
49. Bachran C, Sutherland M, Heisler I, Hebestreit P, Melzig MF, Fuchs H. The saponin-mediated enhanced uptake of targeted saporin-based drugs is strongly dependent on the saponin structure. Exp Biol Med (Maywood) 2006 231 : 412 20.
50. Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan SA. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 2004 7 : 265 73.
51. Wandel C, Kim RB, Guengerich FP, Wood AJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 2000 28 : 895 8.
52. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002 303 : 323 32.
53. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 2002 71 : 1149 60.
54. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999 59 : 3944 8.
55. Bhattaram VA, Graefe U, Kohlert C, Veit M, Derendorf H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002 9 (Suppl 3 1 33.
56. Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992 340 : 1136 9.
57. Fourtillan JB, Brisson AM, Girault J, Ingrand I, Decourt JP, Drieu K et al. [Pharmacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. Therapie 1995 50 : 137 44.
58. Kressmann S, Biber A, Wonnemann M, Schug B, Blume HH, Muller WE. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol 2002 54 : 1507 14.
59. Schulz HU, Schurer M, Bassler D, Weiser D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Arzneimittelforschung 2005 55 : 561 8.
60. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996 40 : 2087 93.
61. Bassler D, Okpanyi S, Schrodter A, Loew D, Schurer M, Schulz HU. Bioavailability of beta-aescin from horse chestnut seed extract: comparative clinical studies of two Galenic formulations. Adv Ther 2003 20 : 295 304.
62. Lang W, Mennicke WH. [Pharmacokinetic studies on triatiated aescin in the mouse and rat]. Arzneimittelforschung 1972 22 : 1928 32.
63. Mauri P, Simonetti P, Gardana C, Minoggio M, Morazzoni P, Bombardelli E et al. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun Mass Spectrom 2001 15 : 929 34.
64. Grenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther 2006 79 : 255 62.
65. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 2000 38 : 161 7.
66. Malingre MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001 19 : 1160 6.
67. Meerum Terwogt JM, Malingre MM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Koopman FJ et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999 5 : 3379 84.
68. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999 33 : 680 2.
69. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004 76 : 73 84.